Rituximab, a chimeric anti-CD20 monoclonal antibody, is commonly used for complicated pediatric nephrotic syndrome (e.g., steroid-dependent or frequently relapsing disease). Post-rituximab hypogammaglobulinemia is a recognized adverse effect that may predispose to severe, including fatal, infections. We conducted a systematic review to estimate the incidence proportion of hypogammaglobulinemia after rituximab and the frequency of concomitant infections in children with nephrotic syndrome. We conducted a systematic review of five databases (1974–2024) for English-language studies enrolling children with nephrotic syndrome who received ≥ 1 dose of rituximab. Hypogammaglobulinemia was defined as an IgG concentration > 2 SD below the age-specific reference value. Of 2681 screened publications, 33 were eligible for meta-analysis. The pooled incidence of hypogammaglobulinemia in children with nephrotic syndrome receiving rituximab was 11.4% (95% CI, 6.4, 19.5). Patients who received rituximab were at increased risk of hypogammaglobulinemia with a risk ratio of 1.81 (95% CI, 1.46, 2.25; equivalent to 68 additional cases per 1000 patients). In 517 episodes of hypogammaglobulinemia, 93 (18%) infections occurred, four of which were fatal. Conclusion: Hypogammaglobulinemia is a common side effect of rituximab that can result in life-threatening infections. The risk of hypogammaglobulinemia and infections should be weighed against the effectiveness of rituximab for nephrotic syndrome management. Prospero registration: CRD42024536465.<Table Float="No" ID="Taba"> <tgroup cols="1"> <colspec align="left" colname="c1" colnum="1" /> <tbody> <row> <entry align="left" colname="c1"> What is Known: • Rituximab, a chimeric anti-CD20 monoclonal antibody, is commonly used for complicated pediatric nephrotic syndrome. • Post-rituximab hypogammaglobulinemia is a recognized adverse effect that may predispose to severe, including fatal, infections; however, the magnitude of risk of poorly understood in pediatric population. </entry> </row> <row> <entry align="left" colname="c1"> What is New: • The pooled incidence of hypogammaglobulinemia in children with nephrotic syndrome receiving rituximab was 11.4%. Rituximab exposure was associated with a significantly higher risk of hypogammaglobulinemia compared with children not receiving rituximab (risk ratio 1.81). • In 517 episodes of hypogammaglobulinemia, 93 (18%) infections occurred, four of which were fatal. </entry> </row> </tbody> </tgroup> </Table>

Rituximab-induced hypogammaglobulinemia in childhood nephrotic syndrome: a systematic review and meta-analysis

期刊论文
发表日期：

2026年3月17日

查看全文

Jason Chung,
Zinnia Chung,
Andrew Yu,
Cal Robinson,
Joycelyne Ewusie,
Andrew M. South,
Arvind Bagga,
Abdulaziz Bamhraz,
Rajiv Sinha,
Rauda AlKhoori,
Yuanxin Xue,
Rahul Chanchlani

摘要

Rituximab, a chimeric anti-CD20 monoclonal antibody, is commonly used for complicated pediatric nephrotic syndrome (e.g., steroid-dependent or frequently relapsing disease). Post-rituximab hypogammaglobulinemia is a recognized adverse effect that may predispose to severe, including fatal, infections. We conducted a systematic review to estimate the incidence proportion of hypogammaglobulinemia after rituximab and the frequency of concomitant infections in children with nephrotic syndrome. We conducted a systematic review of five databases (1974–2024) for English-language studies enrolling children with nephrotic syndrome who received ≥ 1 dose of rituximab. Hypogammaglobulinemia was defined as an IgG concentration > 2 SD below the age-specific reference value. Of 2681 screened publications, 33 were eligible for meta-analysis. The pooled incidence of hypogammaglobulinemia in children with nephrotic syndrome receiving rituximab was 11.4% (95% CI, 6.4, 19.5). Patients who received rituximab were at increased risk of hypogammaglobulinemia with a risk ratio of 1.81 (95% CI, 1.46, 2.25; equivalent to 68 additional cases per 1000 patients). In 517 episodes of hypogammaglobulinemia, 93 (18%) infections occurred, four of which were fatal.

Conclusion: Hypogammaglobulinemia is a common side effect of rituximab that can result in life-threatening infections. The risk of hypogammaglobulinemia and infections should be weighed against the effectiveness of rituximab for nephrotic syndrome management.

Prospero registration: CRD42024536465.

What is Known:

• Rituximab, a chimeric anti-CD20 monoclonal antibody, is commonly used for complicated pediatric nephrotic syndrome.

• Post-rituximab hypogammaglobulinemia is a recognized adverse effect that may predispose to severe, including fatal, infections; however, the magnitude of risk of poorly understood in pediatric population.

What is New:

• The pooled incidence of hypogammaglobulinemia in children with nephrotic syndrome receiving rituximab was 11.4%. Rituximab exposure was associated with a significantly higher risk of hypogammaglobulinemia compared with children not receiving rituximab (risk ratio 1.81).

• In 517 episodes of hypogammaglobulinemia, 93 (18%) infections occurred, four of which were fatal.